系统综述:炎症性肠病治疗反应的预测性生物标志物——个体化医学尚处起步阶段
该研究于2018年1月30日检索MEDLINE、EMBASE和Cochrane Library,系统综述炎症性肠病治疗反应的预测性生物标志物,共纳入92篇文章。多数研究聚焦抗TNF药物治疗反应的预测,研究间异质性大,目前尚无生物标志物足以用于临床。
要点
- 共纳入92篇文章,多数评估抗TNF药物治疗反应的预测性生物标志物。
- 研究间在生物标志物种类和反应定义上存在显著异质性。
- 目前尚无生物标志物对临床使用具有足够的预测价值。
核心结论
- 预测性生物标志物的探索仍处于起步阶段,现有证据有限。
- 未来研究应在前瞻性试验中考虑患者高度异质性并采用客观的反应评估。
- 预测模型最可能由来自整合组学层面的多种分子标志物与临床特征组合构成。
研究设计与样本
- 系统综述,于2018年1月30日检索MEDLINE、EMBASE和Cochrane Library。
- 纳入报告儿童和成人炎症性肠病人群治疗反应预测性生物标志物的回顾性、前瞻性、非对照和对照研究。
- 采用QUIPS工具评估纳入研究的方法学质量。
- 因预期异质性大且数据有限,计划进行定性而非定量评估。
主要发现
- 共识别10638条文献,92篇文章符合纳入标准。
- 评估了多种潜在的DNA、mRNA和蛋白标志物作为预测性生物标志物。
- 多数研究聚焦于预测抗TNF药物的治疗反应。
- 研究间在所研究的生物标志物和反应定义两方面均存在显著异质性。
- 无一项纳入研究在全部六个领域均获得低偏倚风险评级。
临床怎么用
- 目前尚无生物标志物对临床使用具有足够的预测价值。
局限性
- 研究间在所研究的生物标志物和反应定义两方面均存在显著异质性。
- 无一项纳入研究在全部六个领域均获得低偏倚风险评级。
- 因预期异质性大且数据有限,计划进行定性而非定量评估。
- 现有证据有限,预测性生物标志物的探索仍处于起步阶段。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inflammatory bowel disease (IBD) is characterised by substantial heterogeneity in treatment response. With an expanding number of therapeutic agents, identifying optimal treatment at the patient level remains a major challenge. AIM: To systematically review the available literature on predictive biomarkers of therapeutic response in IBD. METHODS: An electronic literature search was performed on 30 January 2018 using MEDLINE, EMBASE and the Cochrane Library. Retrospective, prospective, uncontrolled and controlled studies reporting on biomarkers predicting therapeutic response in paediatric and adult IBD populations were eligible for inclusion. The methodological quality of the included studies was assessed using the QUIPS tool. Due to anticipated heterogeneity and limited data, a qualitative, rather than quantitative, assessment was planned. RESULTS: Of the 10 638 citations identified, 92 articles met the inclusion criteria. Several potential DNA, mRNA and protein markers were evaluated as predictive biomarkers. Most studies focused on predicting response to anti-TNF agents. Substantial between-study heterogeneity was identified with respect to both the biomarkers studied and the definition of response. None of the included studies received a low risk of bias rating for all six domains. Currently, none of the biomarkers is sufficiently predictive for clinical use. CONCLUSIONS: The search for predictive biomarkers is still in its infancy and current evidence is limited. Future research efforts should take into account the high patient heterogeneity within prospective trials with objective response assessment. Predictive models will most likely comprise a combination of several molecular markers from integrated omics-levels and clinical characteristics.
引用
- Stevens TW, Matheeuwsen M, Lönnkvist MH, et al. Systematic review: predictive biomarkers of therapeutic response in inflammatory bowel disease-personalised medicine in its infancy. Aliment Pharmacol Ther. 2018. PMID: 30378142. doi:10.1111/apt.15033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。